ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-26 08:30 |
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectoc…
|
French | 164.4 KB | ||
| 2024-09-26 08:30 |
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the U…
|
English | 14.7 KB | ||
| 2024-09-25 22:01 |
Abivax fait le point sur la stratégie du programme de traitement combiné dans l…
|
French | 144.1 KB | ||
| 2024-09-25 22:01 |
Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strate…
|
English | 13.2 KB | ||
| 2024-09-19 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 97.3 KB | ||
| 2024-09-09 22:01 |
Abivax présente ses résultats financiers du premier semestre 2024
|
French | 223.1 KB | ||
| 2024-09-09 22:01 |
Abivax presents first-half 2024 financial results
|
English | 26.7 KB | ||
| 2024-09-09 22:00 |
Rapport financier semestriel 2024
|
French | 5.6 MB | ||
| 2024-09-09 00:00 |
Rapport CAC sur l'information financière semestrielle 2024
|
French | 5.8 MB | ||
| 2024-09-09 00:00 |
Lettre d'affirmation sur les comptes semestriels 2024
|
French | 501.9 KB | ||
| 2024-09-09 00:00 |
Attestation du responsable du Rapport financier semestriel 2024
|
French | 222.2 KB | ||
| 2024-08-29 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 97.5 KB | ||
| 2024-08-06 08:30 |
Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai …
|
French | 134.6 KB | ||
| 2024-08-06 08:30 |
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
|
English | 9.6 KB | ||
| 2024-07-23 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 96.9 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
